Citations

Clear

1446 citation(s) found for "Howard, F".

Epidemiologic Features of Recovery From SARS-CoV-2 Infection
Oelsner, Elizabeth C. , Sun, Yifei , Andrews, Howard , Carson, April P. , Cushman, Mary , Demmer, Ryan T. , Elkind, Mitchell S.V. , Gallo, Linda C. , Kandula, Namratha R. , Kaplan, Robert C. , Kucharska-Newton, Anna M., Lee, Joyce , Norwood, Arnita F. , Ortega, Victor E. , Gabriel, Kelley Pettee , Sotres‐Alvarez, Daniela , Shikany, James M., Thyagarajan, Bharat , Umans, Jason G. , Wenzel, Sally E. , Woodruff, Prescott G. , Zhang, Ying , Kucharska‐Newton, Anna , Carson, April P , Thyagarajan, Bharat , Oelsner, Elizabeth C , Kucharska-Newton, Anna M , Demmer, Ryan T , Lee, Joyce S , Wenzel, Sally E , Balte, Pallavi , Allen, Norrina B. , Cole, Shelley A. , Coresh, Josef , Couper, David , Daviglus, Martha , Gutierrez, Jose D., Howard, Virginia J. , Isasi, Carmen R. , Judd, Suzanne E. , Kanaya, Alka M , Kinney, Gregory L. , Lackland, Daniel T. , Make, Barry J. , Min, Yuan‐I , Murabito, Joanne M. , Psaty, Bruce M. , Regan, Elizabeth Anne , Schwartz, David A. , Tracy, Russell P. , Vasan, Ramachandran S. , Xanthakis, Vanessa , Post, Wendy S. , Wenzel, Sally E.

Mayo Clinic

JAMA Network Open | June 17, 2024 | Volume: 7 | Issue: 6 | Pages: e2417440

10.1001/jamanetworkopen.2024.17440 | PMID 38884994 Get It

ImportancePersistent symptoms and disability following SARS-CoV-2 infection, known as post–COVID-19 condition or “long COVID,” are frequently reported and pose a substantial personal and societal burden.ObjectiveTo determine time to recovery following SARS-CoV-2 infection and identify factors associated with recovery by 90 days.Design, Setting, and ParticipantsFor this prospective cohort study, standardized ascertainment of SARS-CoV-2 infection was conducted starting in April 1, 2020, across 14 ongoing National Institutes of Health–funded cohorts that have enrolled and followed participants since 1971. This report includes data collected through February 28, 2023, on adults aged 18 years or older with self-reported SARS-CoV-2 infection.ExposurePreinfection health conditions and lifestyle factors assessed before and during the pandemic via prepandemic examinations and pandemic-era questionnaires.Main Outcomes and MeasuresProbability of nonrecovery by 90 days and restricted mean recovery times were estimated using Kaplan-Meier curves, and Cox proportional hazards regression was performed to assess multivariable-adjusted associations with recovery by 90 days.ResultsOf 4708 participants with self-reported SARS-CoV-2 infection (mean [SD] age, 61.3 [13.8] years; 2952 women [62.7%]), an estimated 22.5% (95% CI, 21.2%-23.7%) did not recover by 90 days post infection. Median (IQR) time to recovery was 20 (8-75) days. By 90 days post infection, there were significant differences in restricted mean recovery time according to sociodemographic, clinical, and lifestyle characteristics, particularly by acute infection severity (outpatient vs critical hospitalization, 32.9 days [95% CI, 31.9-33.9 days] vs 57.6 days [95% CI, 51.9-63.3 days]; log-rank P < .001). Recovery by 90 days post infection was associated with vaccination prior to infection (hazard ratio [HR], 1.30; 95% CI, 1.11-1.51) and infection during the sixth (Omicron variant) vs first wave (HR, 1.25; 95% CI, 1.06-1.49). These associations were mediated by reduced severity of acute infection (33.4% and 17.6%, respectively). Recovery was unfavorably associated with female sex (HR, 0.85; 95% CI, 0.79-0.92) and prepandemic clinical cardiovascular disease (HR, 0.84; 95% CI, 0.71-0.99). No significant multivariable-adjusted associations were observed for age, educational attainment, smoking history, obesity, diabetes, chronic kidney disease, asthma, chronic obstructive pulmonary disease, or elevated depressive symptoms. Results were similar for reinfections.Conclusions and RelevanceIn this cohort study, more than 1 in 5 adults did not recover within 3 months of SARS-CoV-2 infection. Recovery within 3 months was less likely in women and those with preexisting cardiovascular disease and more likely in those with COVID-19 vaccination or infection during the Omicron variant wave.
Expression of metabolic genes associated with changes in brain structure across the lifespan affects patients (pts) outcomes in metastatic colorectal cancer (mCRC): Data from CALGB/SWOG 80405 (Alliance).
Millstein, Joshua , Yang, Yan , Algaze, Sandra , Ashouri, Karam , Wong, Alexandra , Lo, Jae Ho, Torres‐Gonzalez, Lesly , Zhang, Wu, Höchster, Howard S. , Innocenti, Federico , Lenz, Heinz‐Josef , Battaglin, Francesca , Yang, Yan , Soni, Shivani , Arai, Hiroyuki , Mittal, Pooja , Jayachandran, Priya , Ou, Fang‐Shu , Venook, Alan P.

Mayo Clinic

Journal of Clinical Oncology | June 17, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 3144-3144

10.1200/jco.2024.42.16_suppl.3144 Get It

3144 Background: Longitudinal brain structure changes across the lifespan are associated with neurodegenerative disorders. We previously showed that genetic variants in dopamine and Parkinson’s disease genes are predictive and prognostic in mCRC. Indeed, the brain-gut axis is emerging as a critical player in CRC biology. Hence, we investigated whether the tumor gene expression of 3 metabolic genes involved in brain development and aging could affect treatment response in patients enrolled in the CALGB/SWOG 80405 trial. Methods: 433 mCRC pts treated with either bevacizumab (bev, n = 226) or cetuximab (cet, n = 207) in combination with first-line chemotherapy were included in the analysis. RNA was isolated from FFPE tumor samples and sequenced on the HiSeq 2500 (Illumina). Overall survival (OS) and progression-free survival (PFS) were compared between groups of pts categorized by tertiles of expression of 3 genes: APOE, DACH1, and GPR139. Likelihood ratio tests, hazard ratios and 95% confidence intervals were computed from multivariate Cox proportional hazards models, adjusting for age, sex, ethnicity, ECOG PS, tumor location, number of metastatic sites, KRAS, MSI status, and treatment. Logrank P-values describe differences without adjustment for patient characteristics. Results: Both APOE and DACH1 (but not GPR139) met the 0.05 false discovery rate threshold for association with both PFS ( P = .00085, P = .015) and OS ( P = .021, P = .021, respectively) in the full Cox models. In cet-treated pts, APOE-high (H) showed significantly shorter PFS (median 9.2 vs 11.8 vs 13.0 months (mo), high vs low (as reference) logrank P = .0021) and OS (median 21.9 vs 35.8 vs 34.6 mo; logrank P = .0017) compared to APOE-median and -low, respectively. Opposite results were observed for DACH1, where DACH1-H tumors had longer PFS (median 14.5 vs 10.6 vs 8.07 mo; logrank P = .0011) and OS (median 39.4 vs 30.9 vs 21.5 mo; logrank P = .0021) when treated with cet. In bev-treated pts, similar results were observed with APOE-H showing shorter OS (median 25.8 vs 26.3 vs 37.5 mo; logrank P = .0016) and DACH1-H longer OS (median 36.5 vs 28.3 vs 22.4 mo; logrank P = .0017). No significant gene-treatment interaction was observed for either gene for PFS and OS. Conclusions: The tumor expression of metabolic genes associated with changes in the brain structure was prognostic in mCRC pts treated with first-line therapy. Notably, APOE and DACH1 have been recently reported to play a role in CRC where APOE overexpression has been associated with aggressive biological behavior whereas DACH1 has been shown to suppress CRC cell growth and invasion. Our results support this evidence and suggest that further investigation into the role of APOE and DACH1 in CRC biology and into their potential as targets for drug development is warranted. Trial Identifier: NCT00265850.
Somatic epimutations cap genetic determinism in the human diploid chromatin epigenome
Vollger, Mitchell R. , Swanson, Elliott , Neph, Shane , Dubocanin, Danilo, Ho, Ching‐Huang , Cheng, Y. H. Hank, Ranchalis, Jane , Munson, Katherine M. , Sedeño-Cortés, Adriana E. , Mudeppa, Devaraja G., Fondrie, William E. , Bohaczuk, Stephanie C. , Dippel, Maxwell A., Mao, Yizi , Parmalee, Nancy L. , Garcia, Gage H. , Meyer, Jeffrey G., Cicek, Mine S., Witten, Daniela , Ray, John , Swanson, Elliott G , Neph, Shane J , Ranchalis, Jane , Munson, Katherine M , Ho, Ching-Huang , Sedeño-Cortés, Adriana E , Fondrie, William E , Bohaczuk, Stephanie C , Mao, Yizi , Mallory, Benjamin J , Harvey, William T , Kwon, Younjun , Garcia, Gage H , Hoekzema, Kendra , Cicek, Mine , Eichler, Evan E , Noble, William S , Bennett, James T , Ray, John P , Stergachis, Andrew B , Dubocanin, Danilo, Cheng, Y. H. Hank, Mudeppa, Devaraja G., Dippel, Maxwell A.

Mayo Clinic

No container title available | June 16, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2024.06.14.599122 | PMID 40501892 Get It

Diploid human cells contain two non-identical genomes, and differences in their regulation underlie human development and disease. We present Fiber-seq Inferred Regulatory Elements (FIRE) and show that FIRE provides a more comprehensive and quantitative snapshot of the accessible chromatin landscape across the 6 Gbp diploid human genome, overcoming previously unrecognized biases in existing regulatory element catalogs. FIRE enables comprehensive detection of haplotype-selective chromatin accessibility (HSCA), exposing novel imprinted elements lacking underlying parent-of-origin CpG methylation differences, and gene regulatory modules that permit genes to escape X chromosome inactivation. We uncover that the human leukocyte antigen (HLA) locus harbors the most HSCA in immune cells, where we resolve specific transcription factor (TF) binding events disrupted by disease-associated variants. Finally, we demonstrate that the regulatory landscape of a cell is littered with autosomal somatic chromatin epimutations that are propagated by clonal expansions to create mitotically stable and non-genetically deterministic chromatin alterations.
Upstream regulation of neurotransmitter signaling genes in metastatic colorectal cancer (mCRC) patients: Data from CALGB/SWOG 80405 trial (Alliance) and MONSTAR-SCREEN-2.
Millstein, Joshua , Yang, Yan , Algaze, Sandra, Ashouri, Karam , Mittal, Pooja, Torres‐Gonzalez, Lesly , Zhang, Wu, Höchster, Howard S. , Innocenti, Federico , Hashimoto, Tadayoshi , Lenz, Heinz‐Josef , Battaglin, Francesca , Soni, Shivani , Algaze, Sandra , Mittal, Pooja , Ou, Fang‐Shu , Venook, Alan P. , Mumenthaler, Shannon M. , Fujisawa, Takao , Nakamura, Yoshiaki , Bando, Hideaki , Yoshino, Takayuki

Mayo Clinic

Journal of Clinical Oncology | June 4, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 3523-3523

10.1200/jco.2024.42.16_suppl.3523 Get It

3523 Background: Evidence suggests neurotransmitter signaling may play a crucial role in tumorigenesis of gastrointestinal (GI) cancers, including migration, proliferation, and apoptosis, as well as angiogenesis and the microenvironment. We developed and applied a strategy to identify upstream regulators of neurotransmitters and their associations with patient outcomes. Methods: Prior literature yielded 85 neurotransmitter signaling genes mapped to RNA-seq gene expression in tumor tissue from 545 patients with mCRC enrolled in the phase III CALGB/SWOG 80405 trial. These samples were also sequenced by FoundationOne CDx for DNA damage. Using Cox proportional hazards regression, we identified a subset of CDx genes associated with overall survival (OS) or progression-free survival (PFS). We extended the Causal Inference Test (CIT) for time-to-event data and identified a subset of the 85 signaling genes consistent with mediation of DNA mutation effects on OS and PFS. Another CIT analysis identified potential upstream neurotransmitter regulators, gene expression mediators of mutation effects on the signaling genes. Top genes were then assessed in whole-transcriptome sequencing (WTS) expression data with Caris MI profile collected from 398 patients with advanced CRC enrolled in the MONSTAR-SCREEN-2 trial. Results: At the 0.05 alpha level, we identified 20 signaling genes with gene expression associated with PFS and/or OS, and 68 genes with evidence of DNA mutations associated with PFS and/or OS. False discovery rate (FDR) < 0.05 was applied to filter the 56,674 expression features on PFS and OS associations, yielding 173 unique genes as possible mediators. The CIT yielded 53 putative mediators at FDR < 0.05, suggesting upstream regulation of neurotransmitter signaling. Five genes were identified as targeting at least 8 signaling genes each, PIGU, ANO9, LY6G6D, and GPR160, and FSCN1, where the first 4 are favorable and only FSCN1 is a poorer prognostic. Following up on these 5 genes in MONSTAR-SCREEN-2 by dichotomizing at the median value of WTS expression, 3 were nominally associated with OS, PIGU ( P = 0.050; HR, 0.59; 95%CI, 0.34-1.00), ANO9( P = 0.029; HR, 0.55; 95%CI, 0.32-0.95), LY6G6D( P = 0.0024; HR, 0.44; 95%CI, 0.25-0.76), and FSCN1 was suggestive ( P = 0.079; HR, 1.62; 95%CI, 0.94-2.77), with direction of effects in agreement with 80405 results for all four. Conclusions: Our novel approach identified previously unknown upstream regulators of neurotransmitter signaling associated with treatment outcomes in mCRC. PIGU, FSCN1, and LY6G6D have been suggested in prior literature as targets for CRC and ANO9 has been suggested as a target for GI cancer. These results bolster the strategy of using mediation analysis with large-scale molecular data to identify new therapeutic targets in CRC. NCT00265850.
Living Kidney Donor Candidates With Nephrolithiasis: Examination of Current Practices
Zhang, Nan , Khamash, Hasan , Porter, Ivan E. , Keddis, Mira T. , Howard, Matthew A. , Rule, Andrew D. , D’Costa, Matthew R. , Wadei, Hani M. , Jadlowiec, Caroline C.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 33 | Issue: 11S | Pages: 830-830

10.1681/asn.20223311s1830a Get It

Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer
Lee, W. Robert , Dignam, James J., Amin, Mahul B. , Bruner, Deborah Watkins , Low, Daniel A. , Shah, Amit B. , D’Souza, David , Michalski, Jeff M. , Dayes, Ian S. , Seaward, Samantha A. , Hall, William A. , Nguyen, Paul L. , Pisansky, Thomas M. , Faria, Sergio , Chen, Yuhchyau , Rodgers, Joseph P., Bruner, Deborah , Swanson, Gregory P , Michalski, Jeff M , Dayes, Ian S , Seaward, Samantha A , Hall, William A , Sandler, Howard M , Swanson, Gregory P. , Sandler, Howard M.

Mayo Clinic

Journal of Clinical Oncology | May 17, 2024 | Volume: 42 | Issue: 20 | Pages: 2377-2381

10.1200/jco.23.02445 | PMID 38759121 Get It

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. NRG Oncology RTOG 0415 is a randomized phase III noninferiority (NI) clinical trial comparing conventional fractionation (73.8 Gy in 41 fractions) radiotherapy (C-RT) with hypofractionation (H-RT; 70 Gy in 28) in patients with low-risk prostate cancer. The study included 1,092 protocol-eligible patients initially reported in 2016 with a median follow-up of 5.8 years. Updated results with median follow-up of 12.8 years are now presented. The estimated 12-year disease-free survival (DFS) is 56.1% (95% CI, 51.5 to 60.5) for C-RT and 61.8% (95% CI, 57.2 to 66.0) for H-RT. The DFS hazard ratio (H-RT/C-RT) is 0.85 (95% CI, 0.71 to 1.03), confirming NI ( P < .001). Twelve-year cumulative incidence of biochemical failure (BF) was 17.0% (95% CI, 13.8 to 20.5) for C-RT and 9.9% (95% CI, 7.5 to 12.6) for H-RT. The HR (H-RT/C-RT) comparing biochemical recurrence between the two arms was 0.55 (95% CI, 0.39 to 0.78). Late grade ≥3 GI adverse event (AE) incidence is 3.2% (C-RT) versus 4.4% (H-RT), with relative risk (RR) for H-RT versus C-RT 1.39 (95% CI, 0.75 to 2.55). Late grade ≥3 genitourinary (GU) AE incidence is 3.4% (C-RT) versus 4.2% (H-RT), RR 1.26 (95% CI, 0.69 to 2.30). Long-term DFS is noninferior with H-RT compared with C-RT. BF is less with H-RT. No significant differences in late grade ≥3 GI/GU AEs were observed between assignments (ClinicalTrials.gov identifier: NCT00331773 ).
CKD Stage/Duration and Cardiovascular (CV) Risk Factors in Children With Proteinuric Glomerulopathies (GD)
Sethna, Christine B. , Meyers, Kevin , Srivastava, Tarak, Massengill, Susan F. , Weaver, Donald J. , Gibson, Keisha L. , Dell, Katherine M., Tran, Cheryl L. , Mitchell, Elizabeth , Tuttle, Katherine R. , Gipson, Debbie S , Trachtman, Howard

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 33 | Issue: 11S | Pages: 215-215

10.1681/asn.20223311s1215b Get It

Molecular neuroimaging in dominantly inherited versus sporadic early-onset Alzheimer’s disease
Llibre‐Guerra, Jorge J. , Gordon, Brian A. , Hassenstab, Jason , Kramer, Joel H. , Morris, John C. , Mundada, Nidhi S. , Perrin, Richard J. , Rosen, Howard J. , Soleimani‐Meigooni, David N. , Strom, Amelia , Tsoy, Elena , Xiong, Chengjie , Chrem, Patricio, Vázquez, Silvia , Berman, Sarah , Chhatwal, Jasmeer P. , Masters, Colin L. , Farlow, Martin R. , Xiong, Chengjie , Salloway, Stephen , Day, Gregory S. , Gorno‐Tempini, Maria Luisa , Boxer, Adam L. , Joie, Renaud La , Rabinovici, Gil D. , Llibre-Guerra, Jorge J , Gordon, Brian A , Miller, Zachary , Morris, John C , Soleimani-Meigooni, David , Chhatwal, Jasmeer , Masters, Colin L , Xiong, Chengjie , La Joie, Renaud , Bateman, Randall J , Rabinovici, Gil D , Day, Gregory S , Hassenstab, Jason , Berman, Sarah , Iaccarino, Leonardo , McDade, Eric , Edwards, Lauren , Benzinger, Tammie L.S. , Li, Yan , Miller, Bruce L. , Miller, Zachary , Wang, Guoqiao , Allegri, Ricardo , Jucker, Mathias , Fox, Nick C. , Bateman, Randall J.

Mayo Clinic

Brain Communications | May 3, 2024 | Volume: 6 | Issue: 3 | Pages: No page available

10.1093/braincomms/fcae159 | PMID 38784820 Get It

Abstract Approximately 5% of Alzheimer’s disease patients develop symptoms before age 65 (early-onset Alzheimer’s disease), with either sporadic (sporadic early-onset Alzheimer’s disease) or dominantly inherited (dominantly inherited Alzheimer’s disease) presentations. Both sporadic early-onset Alzheimer’s disease and dominantly inherited Alzheimer’s disease are characterized by brain amyloid-β accumulation, tau tangles, hypometabolism and neurodegeneration, but differences in topography and magnitude of these pathological changes are not fully elucidated. In this study, we directly compared patterns of amyloid-β plaque deposition and glucose hypometabolism in sporadic early-onset Alzheimer’s disease and dominantly inherited Alzheimer’s disease individuals. Our analysis included 134 symptomatic sporadic early-onset Alzheimer’s disease amyloid-Positron Emission Tomography (PET)-positive cases from the University of California, San Francisco, Alzheimer’s Disease Research Center (mean ± SD age 59.7 ± 5.6 years), 89 symptomatic dominantly inherited Alzheimer’s disease cases (age 45.8 ± 9.3 years) and 102 cognitively unimpaired non-mutation carriers from the Dominantly Inherited Alzheimer Network study (age 44.9 ± 9.2). Each group underwent clinical and cognitive examinations, 11C-labelled Pittsburgh Compound B-PET and structural MRI. 18F-Fluorodeoxyglucose-PET was also available for most participants. Positron Emission Tomography scans from both studies were uniformly processed to obtain a standardized uptake value ratio (PIB50–70 cerebellar grey reference and FDG30–60 pons reference) images. Statistical analyses included pairwise global and voxelwise group comparisons and group-independent component analyses. Analyses were performed also adjusting for covariates including age, sex, Mini-Mental State Examination, apolipoprotein ε4 status and average composite cortical of standardized uptake value ratio. Compared with dominantly inherited Alzheimer’s disease, sporadic early-onset Alzheimer’s disease participants were older at age of onset (mean ± SD, 54.8 ± 8.2 versus 41.9 ± 8.2, Cohen’s d = 1.91), with more years of education (16.4 ± 2.8 versus 13.5 ± 3.2, d = 1) and more likely to be apolipoprotein ε4 carriers (54.6% ε4 versus 28.1%, Cramer’s V = 0.26), but similar Mini-Mental State Examination (20.6 ± 6.1 versus 21.2 ± 7.4, d = 0.08). Sporadic early-onset Alzheimer’s disease had higher global cortical Pittsburgh Compound B-PET binding (mean ± SD standardized uptake value ratio, 1.92 ± 0.29 versus 1.58 ± 0.44, d = 0.96) and greater global cortical 18F-fluorodeoxyglucose-PET hypometabolism (mean ± SD standardized uptake value ratio, 1.32 ± 0.1 versus 1.39 ± 0.19, d = 0.48) compared with dominantly inherited Alzheimer’s disease. Fully adjusted comparisons demonstrated relatively higher Pittsburgh Compound B-PET standardized uptake value ratio in the medial occipital, thalami, basal ganglia and medial/dorsal frontal regions in dominantly inherited Alzheimer’s disease versus sporadic early-onset Alzheimer’s disease. Sporadic early-onset Alzheimer’s disease showed relatively greater 18F-fluorodeoxyglucose-PET hypometabolism in Alzheimer’s disease signature temporoparietal regions and caudate nuclei, whereas dominantly inherited Alzheimer’s disease showed relatively greater hypometabolism in frontal white matter and pericentral regions. Independent component analyses largely replicated these findings by highlighting common and unique Pittsburgh Compound B-PET and 18F-fluorodeoxyglucose-PET binding patterns. In summary, our findings suggest both common and distinct patterns of amyloid and glucose hypometabolism in sporadic and dominantly inherited early-onset Alzheimer’s disease.
Evidence-based screening, clinical care and health education recommendations for Alaska Native peoples with prediabetes living in southcentral Alaska: findings from the Alaska EARTH follow-up study
Koller, Kathryn R. , Nash, Sarah H. , Beans, Julie A. , Day, Gretchen , Hiratsuka, Vanessa Y. , Lin, Ai-Ling, Narayanan, Meera, Patten, Christi A. , Hammock, Sherry A. , Howard, Barbara V. , Umans, Jason G. , Day, Gretchen M , Patten, Christi , Koller, Kathryn , Hiratsuka, Vanessa , Beans, Julie A

Mayo Clinic

International Journal of Circumpolar Health | May 1, 2024 | Volume: 83 | Issue: 1 | Pages: No page available

10.1080/22423982.2024.2343143 | PMID 38691019 Get It